Efficacy of GLP-1 receptor agonists
Meta-analyses including data from randomised controlled trials assessing clinically relevant doses of GLP-1 receptor agonists administered for longer periods have been published. The results provide evidence that intervention with clinical relevant doses of currently available GLP-1 receptor agonists (exenatide, exenatide once-weekly and liraglutide) facilitate reduction in body weight in obese patients both with and without diabetes. GLP-1 receptor agonists also had beneficial effects on the systolic and diastolic blood pressure and cholesterol. For patients with type 2 diabetes, GLP-1 receptor agonists improved glycaemic control (as assessed by HbA1c and fasting plasma glucose) and increased the proportion of patients who achieved the target HbA1c.